Streetbeat News

PXMD

PaxMedica Inc

Employees

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

0.06

Mkt cap

435K

Volume

54K

High

0.06

P/E Ratio

-0.01

52-wk high

1.19

Low

0.04

Div yield

N/A

52-wk low

0.03

PaxMedica, Inc. has received its first patent allowance for a suramin intranasal formulation aimed at treating Autism Spectrum Disorder and other conditions. This patent is granted in China, marking a significant milestone for the company.

Portfolio Pulse from

January 14, 2025 | 1:15 pm

PaxMedica (PXMD) has responded to an emergency request for IV Suramin by announcing it will provide immediate access to PAX-101, its proprietary formulation. This move could potentially impact the company's stock as it demonstrates responsiveness to urgent medical needs and the potential for increased demand for PAX-101.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:41 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Chromocell Therapeutics, Kineta, Portage Biotech, Erasca, MSP Recovery, and Cue Health were among the gainers, with increases ranging from 12.25% to 21.6%. On the downside, Nexalin Technology, iSpecimen, INVO Bioscience, Intelligent Bio Solutions, Trevena, and PaxMedica experienced declines between 9.58% and 18.4%. Notably, MSP Recovery and INVO Bioscience had recent earnings reports influencing their stock movements.

Portfolio Pulse from Benzinga Insights

April 19, 2024 | 12:08 pm

PaxMedica (PXMD) shares surged following an emergency request from the Ministry of Health of Malawi for access to IV suramin, indicating strong international interest in the company's product.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:59 pm

PaxMedica (PXMD) shares surged following an emergency request from the Ministry of Health of Malawi for access to IV suramin, indicating strong international interest in the company's product.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 8:34 pm

PaxMedica, Inc. (NASDAQ: PXMD) has received an emergency request from the Ministry of Health of Malawi for IV suramin (PAX-101) to treat African sleeping sickness amid a drug shortage. The company, focusing on neurological disorders, has completed pivotal batches of PAX-101 and is in discussions with the FDA regarding the impact on its NDA submission plans. PaxMedica's engagement with the FDA also explores the potential for a Priority Review Voucher under the Neglected Tropical Disease program, aiming to ensure a steady supply of suramin.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 8:32 pm

In Tuesday's after-market session, health care stocks saw significant movement. Clene (CLNN) led the gainers with a 54.9% increase, while Telesis Bio (TBIO) experienced the largest drop among the losers, falling 15.9%. Other notable movers included Talphera (TLPH) and Lexaria Bioscience (LEXX) with substantial gains, and Ontrak (OTRK) with a notable decline following its Q4 earnings report.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 8:31 pm

In Tuesday's intraday session, several healthcare stocks experienced significant movements. Palisade Bio, China SXT Pharmaceuticals, Dynatronics, Jaguar Health, BioSig Technologies, and Intra-Cellular Therapies were among the gainers, with increases ranging from 26.49% to 65.1%. Conversely, Calidi Biotherapeutics, Pacific Biosciences, Portage Biotech, Nexalin Technology, PaxMedica, and Adlai Nortye were the losers, with decreases ranging from 17.81% to 58.5%.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 4:31 pm

U.S. stocks saw an uptick with the Dow Jones rising over 300 points, attributed partly to Goldman Sachs' better-than-expected earnings report. Goldman Sachs reported a Q1 revenue of $14.21 billion and EPS of $11.58, surpassing consensus estimates. In other market news, Soligenix, Longeveron, and Organovo Holdings experienced significant share price increases due to positive company developments, while Marinus Pharmaceuticals, ProMIS Neurosciences, and PaxMedica saw their shares decline.

Portfolio Pulse from Avi Kapoor

April 15, 2024 | 2:00 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Soligenix, Longeveron, Cartesian Therapeutics, Biomerica, Allarity Therapeutics, and Envoy Medical were among the gainers, with Soligenix leading by a 95.1% increase. On the downside, Marinus Pharma, TRACON Pharma, Neumora Therapeutics, PaxMedica, Alterity Therapeutics, and SINTX Techs faced declines, with Marinus Pharma dropping by 74.5%. Biomerica's rise was attributed to its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 12:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.